Regenxbio, Moderna Therapeutics and Other Biotech Stocks Posted Gains in a Bad Market Day

Regenxbio, Moderna and Others
Regenxbio (RGNX) announced several poster presentations including interim data from its Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II

This content is for paid subscribers.
Please click here to subscribe or here to log in.